A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Description

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Conditions

Adenocarcinoma of Lung

Talk to us

Study Overview

On this page

Study Details

Study overview

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Condition
Adenocarcinoma of Lung
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Suffolk - Commack (Consent Only), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
  • * The participant is ≥22 years of age on the day of signing informed consent.
  • * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
  • * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
  • * The participant with multiple nodules has one nodule that meets the criteria.
  • * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  • * Patients receiving therapy for concurrent active malignancy
  • * Patients with a history of cardiac arrhythmias and/or pacemaker use
  • * Patients with lung nodules \<1cm
  • * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
  • * Patients with lung nodules that are \<50% solid of any size

Ages Eligible for Study

22 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Prasad Adusumilli, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2027-08